Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SUQ
|
|||
| Former ID |
DIB007138
|
|||
| Drug Name |
ES-285
|
|||
| Synonyms |
Spisulosine-285
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Discontinued in Phase 1 | [1] | |
| Company |
PharmaMar SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H39NO
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCC(C(C)N)O
|
|||
| InChI |
1S/C18H39NO/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20)17(2)19/h17-18,20H,3-16,19H2,1-2H3/t17-,18+/m0/s1
|
|||
| InChIKey |
YRYJJIXWWQLGGV-ZWKOTPCHSA-N
|
|||
| CAS Number |
CAS 196497-48-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:67106
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013684) | |||
| REF 2 | Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol. 2008 Apr 28;584(2-3):237-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.